OPEN-LABEL, UNCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF INEBILIZUMAB IN CHILDREN FROM 2 YEARS TO LESS THAN 18 YEARS OF AGE WITH IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD)

Registry ID

20240202

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

AMGEN CANADA INC

Completion date

2026-05-19

Last update

2025-12-08

Conditions

• IGG4 RELATED DISEASE

Related clinical trials

• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY OF INEBILIZUMAB EFFICACY AND SAFETY IN IGG4 RELATED DISEASE

View on source registry